[1]
|
[1]ROWINSKY E K,ONETTO N,CANETTA R M,et al.Taxol:the first of the taxanes,an important new class of antitumor agents[J].Semin Oncol,1992,19(6):646-662.
|
[2]
|
[2]YAMASAKI M,MURAKAMI I,NAKANO K,et al.Carboplatin plus weekly paclitaxel combined with bevacizumab as first-line treatment for non-small cell Lung cancer[J].Anticancer Res,2017,37(2):923-928.
|
[3]
|
[3]KANG F C,CHEN P J,PAN B S,et al.Apoptotic effect of cordycepin combined with cisplatin and/or paclitaxel on MA-10 mouse Leydig tumor cells[J].Onco Targets Ther,2015,8(1):2345-2360.
|
[4]
|
[4]CADAMURO M,SPAGNUOLO G,SAMBADO L,et al.Low-Dose Paclitaxel Reduces S100A4 Nuclear Import to Inhibit Invasion and Hematogenous Metastasis of Cholangiocarcinoma[J].Cancer Res,2016,76(16):4775-4784.
|
[5]
|
[5]KIM S W,HASANUZZAMAN M,CHO M,et al.Role of14-3-3 sigma in over-expression of P-gp by rifampin and paclitaxel stimulation through interaction with PXR[J].Cell Signal,2017,2(31):124-134.
|
[6]
|
[6]ITO Y,KIKUCHI E,TANAKA N,et al.Down-regulation of NF kappa B activation is an effective therapeutic modality in acquired platinum-resistant bladder cancer[J].BMC Cancer,2015,4(29):324.
|
[7]
|
[7]DZIADYK J M,SUI M,ZHU X,et al.Paclitaxel-induced apoptosis may occur without a prior G2/M-phase arrest[J].Anticancer Res,2004,24(1):27-36.
|
[8]
|
[8]LI S,YANG L,WANG J,et al.Analysis of the chemotherapeutic effects of a propadiene compound on malignant ovarian cancer cells[J].Oncotarget,2016,7(35):57145-57159.
|
[9]
|
[9]YING L,ZHU Z,XU Z,et al.Cancer associated fibroblast-derived hepatocyte growth factor inhibits the paclitaxel-Induced apoptosis of lung cancer A549 cells by up-regulating the PI3K/Akt and GRP78 signaling on a microfluidic platform[J].PLo S One,2015,10(6):e0129593.
|
[10]
|
[10]ZHANG C,ZHANG Z,ZHANG S,et al.Targeting of Wnt/β-catenin by anthelmintic drug pyrvinium enhances sensitivity of ovarian cancer cells to chemotherapy[J].Med Sci Monit,2017,23(16):266-275.
|
[11]
|
[11]SHEN D Y,ZHANG W,ZENG X,et al.Inhibition of Wnt/β-catenin signaling downregulates P-glycoprotein and reverses multi-drug resistance of cholangiocarcinoma[J].Cancer Sci,2013,104(10):1303-1308.
|
[12]
|
[12]AHRENDT S A,RASHID A,CHOW J T,et al.p53 overexpression and K-ras gene mutations in primary sclerosing cholangitis-associated biliary tract cancer[J].J Hepatobiliary Pancreat Surg,2000,7(4):426-431.
|
[13]
|
[14]SUTO T,HABANO W,SUGAI T,et al.Aberrations of the K-ras,p53,and APC genes in extrahepatic bile duct cancer[J].J Surg Oncol,2000,73(3):158-163.
|
[14]
|
[15]KHAN S A,THOMAS H C,TOLEDANO M B,et al.p53Mutations in human cholangiocarcinoma:a review[J].Liver Int,2005,25(4):704-716.
|
[16]周彦明,朱有全,冯颖.癌基因c-Fos、c-Jun在胆系恶性肿瘤中的表达[J].中华普通外科杂志,2002,17(2):123.
|